Immunotherapy

Phase 1, open-label, interventional trial of drug-resistant immunotherapy with activated, gene-modified gamma-delta T cells in patients with newly diagnosed glioblastoma multiforme receiving maintenance temozolomide chemotherapy

Phase 1, open-label, interventional trial to determine the adverse effects and best dose of genetically modified T-cell immunotherapy in treating patients with relapsed or refractory malignant glioma.

Healio spoke with Karen L. Reckamp, MD, MS, medical director of clinical research operations, co-director of the thoracic oncology program, and professor in the department of medical oncology at City of Hope Comprehensive Cancer Center in Duarte, California, about her research in immunotherapy treatments for non-small cell lung cancer and the role of genetics to better target individual therapies for patients with lung cancer.

Healio spoke with Fred R. Hirsch, MD, PhD, professor of medicine and pathology at the University of Colorado Cancer Center in Denver and CEO of the International Association for the Study of Lung Cancer, about the multiple clinical trials being performed in the United States and Europe that study biomarkers and personalized medicine in the field of lung cancer.

Healio spoke with Edward S. Kim, MD, chair of the department of solid tumor oncology at Levine Cancer Institute at Atrium Health in Charlotte, North Carolina, about stress management and how stress hormones can promote epidermal growth factor receptor inhibitor resistance in non-small cell lung cancer.

Immunotherapy drugs have presented new options for treating patients with cancer, including non-small cell lung cancer, but patient selection and toxicity management still present challenges for clinicians.

Black patients with earlier-stage melanoma were more likely than their non-Hispanic white counterparts to experience delayed time from diagnosis to definitive surgery, according to a study.

Timothy Chan, MD, PhD, has been appointed director of Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic.

Despite the success of immunotherapy in the treatment of patients with advanced malignancies, responses in metastatic castration-resistant prostate cancer have been limited.

Nivolumab administered 4 weeks before surgery induced pathologic complete responses and radiographic tumor regressions in about half of a cohort of patients with Merkel cell carcinoma, according to results of the phase 1/phase 2 CheckMate 358 study published in Journal of Clinical Oncology.